Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 1c

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of ($0.57), $0.01 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $126 million versus the consensus estimate of $129.94 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2021 revenue of $600 million, versus the consensus of $618 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• SPS Commerce (SPSC) Tops Q1 EPS by 12c
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance